| ||||
Public Act 097-0872 | ||||
| ||||
| ||||
AN ACT concerning public health.
| ||||
Be it enacted by the People of the State of Illinois,
| ||||
represented in the General Assembly:
| ||||
Section 5. The Illinois Food, Drug and Cosmetic Act is | ||||
amended by changing Sections 2.4, 3.22, 5, and 6 as follows:
| ||||
(410 ILCS 620/2.4) (from Ch. 56 1/2, par. 502.4)
| ||||
Sec. 2.4.
(a) "Drug" means (1) articles recognized in the | ||||
official United
States Pharmacopoeia - National Formulary, | ||||
official Homeopathic Pharmacopoeia
of the United
States, | ||||
United States Dispensatory, or Remington's Practice of | ||||
Pharmacy,
or any supplement to any of them; and (2)
articles | ||||
intended for use in the diagnosis, cure, mitigation, treatment | ||||
or
prevention of disease in man or other animals; and (3) | ||||
articles (other than
food) intended to affect the structure or | ||||
any function of the body of man
or other animals; and (4) | ||||
articles intended for use as a component of any
article | ||||
specified in clause (1), (2) or (3); but does not include | ||||
devices
or their components, parts or accessories.
| ||||
(b) "Synthetic drug product" means any product that | ||||
contains a substance defined as a controlled substance under | ||||
subsections (d) and (e) of Section 204 of the Illinois | ||||
Controlled Substances Act. Products approved by the U.S. Food | ||||
and Drug Administration for human consumption are not synthetic |
drug products. | ||
(Source: P.A. 84-891.)
| ||
(410 ILCS 620/3.22) (from Ch. 56 1/2, par. 503.22)
| ||
Sec. 3.22.
(a) Whoever knowingly distributes, or possesses | ||
with intent to
distribute, human growth hormone for any use in | ||
humans other than the
treatment of a disease or other | ||
recognized medical condition, where the use
has been authorized | ||
by the Secretary of Health and Human Services and under
the | ||
order of a physician, is guilty of a Class 3 felony, and may be | ||
fined
an amount not to exceed $50,000. As used in this Section, | ||
the term "human growth hormone" means somatrem, somatropin, or | ||
an analogue of either of them.
| ||
(b) Whoever distributes, or possesses with intent to | ||
distribute, a synthetic drug product or a drug that is | ||
misbranded under this Act is guilty of a Class 2 felony and may | ||
be fined an amount not to exceed $100,000. A person convicted | ||
of a second or subsequent violation of this Section is guilty | ||
of a Class 1 felony, the fine for which shall not exceed | ||
$250,000. | ||
(c) Whoever falsely advertises a synthetic drug product is | ||
guilty of a Class 3 felony and may be fined an amount not to | ||
exceed $100,000. | ||
(d) Whoever commits any offense set forth in this Section | ||
and the offense
involves an individual under 18 years of age is | ||
punishable by not more than
10 years imprisonment, and twice |
the fine authorized above. Any conviction
for a violation of | ||
this Section shall be considered a violation of the
Illinois | ||
Controlled Substances Act for the purposes of forfeiture under
| ||
Section 505 of such Act. As used in this Section the term | ||
"human growth
hormone" means somatrem, somatropin, or an | ||
analogue of either of them. The
Department of State Police and | ||
Department of Professional Regulation are
authorized to | ||
investigate offenses punishable by this Section.
| ||
(e) Any person convicted under this Section is subject to | ||
the forfeiture provisions set forth in subsections (c), (d), | ||
(e), (f), (g), (h), and (i) of Section 3.23 of this Act. | ||
(Source: P.A. 87-754.)
| ||
(410 ILCS 620/5) (from Ch. 56 1/2, par. 505)
| ||
Sec. 5.
(a) A person who violates any of the provisions of | ||
this Act,
other than Sections 3.22 and 6, is guilty of a Class | ||
C misdemeanor; but if
the violation is committed after a | ||
conviction of such person under this
Section has become final, | ||
the person shall be guilty of a Class A
misdemeanor. A person | ||
who violates the provisions of Section 6 of this Act
is guilty | ||
of a Class A misdemeanor; but if the violation is committed | ||
after
a conviction of such person under this Section has become | ||
final, the person
shall be guilty of a Class 4 felony.
| ||
(b) No person is subject to the penalties of subsection (a) | ||
of this
Section for (1) violating Section 3.1 or 3.3 if he | ||
establishes a guaranty or
undertaking signed by and containing |
the name and address of the person
residing in the State of | ||
Illinois from whom he received the article in good
faith, to | ||
the effect that the article is not adulterated or misbranded
| ||
within the meaning of this Act, designating this Act; or (2) | ||
for having
violated clause (2) of Section 3.16 if such person | ||
acted in good faith and
had no reason to believe that the use | ||
of the punch, die, plate, stone or
other thing involved would | ||
result in a drug being a counterfeit drug, or
for having | ||
violated clause (3) of Section 3.16 if the person doing the act
| ||
or causing it to be done acted in good faith and had no reason | ||
to believe
that the drug was a counterfeit drug.
| ||
(c) No publisher, radio-broadcast licensee, agency or | ||
medium for the
dissemination of an advertisement, except the | ||
manufacturer, packer,
distributor or seller of the article to | ||
which a false advertisement relates
is liable under this | ||
Section for the dissemination of such false
advertisement | ||
unless he has refused on the request of the Director to
furnish | ||
the Director the name and post office address of the | ||
manufacturer,
packer, distributor, seller or advertising | ||
agency residing in the State of
Illinois who causes him to | ||
disseminate such advertisement.
| ||
(d) No person shall be subject to the penalties of | ||
subsection (a) of
this Section for a violation of Section 3 | ||
involving misbranded food if the
violation exists solely | ||
because the food is misbranded under subsection
(c) of Section | ||
11 because of its advertising, and no person shall be
subject |
to the penalties of subsection (a) of this Section for such a
| ||
violation unless the violation is committed with the intent to | ||
defraud
or mislead.
| ||
(Source: P.A. 86-704; 87-754.)
| ||
(410 ILCS 620/6) (from Ch. 56 1/2, par. 506)
| ||
Sec. 6.
(a) When an authorized agent of the Director finds | ||
or has probable
cause to believe that any food, drug, device or | ||
cosmetic is adulterated or
so misbranded as to be dangerous or | ||
fraudulent within the meaning of this
Act , or is in violation | ||
of Section 12, 17 or 17.1 of this Act, or is suspected to be a | ||
synthetic drug product, he or she
shall affix to such article a | ||
tag or other appropriate marking
giving notice that the article | ||
is or is suspected of being adulterated or
misbranded and has | ||
been detained or embargoed and warning all persons not
to | ||
remove or dispose of such article by sale or otherwise until | ||
permission
for removal or disposal is given by such agent or | ||
the court. It is unlawful
for any person to remove or dispose | ||
of such detained or embargoed article
by sale or otherwise | ||
without such permission.
| ||
(b) When an article detained or embargoed under subsection | ||
(a) of this
Section is found by such agent to be adulterated or | ||
misbranded or to be
in violation of Section 12, 17 or 17.1 of | ||
this Act or is suspected to be a synthetic drug product ,
he or | ||
she shall petition the
circuit court in whose jurisdiction the | ||
article is detained or embargoed
for a libel for condemnation |
of such article. When such agent finds that an
article so | ||
detained or embargoed is not adulterated or misbranded or is | ||
not a synthetic drug product , he or
she shall remove the tag or | ||
other marking.
| ||
(c) If the court finds that a detained or embargoed article | ||
is
adulterated or misbranded, such article shall, after entry | ||
of the judgment, be
destroyed at the expense of the claimant | ||
thereof, under the supervision
of such agent, and all court | ||
costs and fees, and storage and other proper
expenses, shall be | ||
taxed against the claimant of such article or his or her
agent. | ||
However, when the adulteration or misbranding can be corrected | ||
by proper
labeling or processing of the article, the court, | ||
after entry of the judgment
and after such costs, fees and | ||
expenses have been paid and a good and
sufficient bond, | ||
conditioned that such article shall be so labeled or
processed, | ||
has been executed, may by order direct that such article be
| ||
delivered to the claimant thereof for such labeling or | ||
processing under the
supervision of an agent of the Director. | ||
The expense of such supervision
shall be paid by the claimant. | ||
The article shall be returned to the claimant
and the bond | ||
shall be discharged on the representation to the court by the
| ||
Director that the article is no longer in violation of this | ||
Act, and that
the expenses of such supervision have been paid.
| ||
(d) Whenever the Director or any of his or her authorized | ||
agents finds
in any room, building, vehicle of transportation | ||
or other structure, any
meat, sea food, poultry, vegetable, |
fruit or other perishable articles
which contain any filthy, | ||
decomposed or putrid substance, or that may be
poisonous or | ||
deleterious to health or otherwise unsafe, the same being
| ||
hereby declared to be a nuisance, the Director or his or her | ||
authorized
agent shall condemn or destroy the same, or in any | ||
other manner render the
same unusable as human food.
| ||
(Source: P.A. 85-564.)
| ||
Section 10. The Illinois Controlled Substances Act is | ||
amended by changing Section 204 as follows: | ||
(720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) | ||
Sec. 204. (a) The controlled substances listed in this | ||
Section are
included in Schedule I. | ||
(b) Unless specifically excepted or unless listed in | ||
another
schedule, any of the following opiates, including their | ||
isomers,
esters, ethers, salts, and salts of isomers, esters, | ||
and ethers,
whenever the existence of such isomers, esters, | ||
ethers and salts is
possible within the specific chemical | ||
designation: | ||
(1) Acetylmethadol; | ||
(1.1) Acetyl-alpha-methylfentanyl | ||
(N-[1-(1-methyl-2-phenethyl)-
| ||
4-piperidinyl]-N-phenylacetamide); | ||
(2) Allylprodine; | ||
(3) Alphacetylmethadol, except
|
levo-alphacetylmethadol (also known as levo-alpha-
| ||
acetylmethadol, levomethadyl acetate, or LAAM); | ||
(4) Alphameprodine; | ||
(5) Alphamethadol; | ||
(6) Alpha-methylfentanyl
| ||
(N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
| ||
propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
| ||
propanilido) piperidine; | ||
(6.1) Alpha-methylthiofentanyl
| ||
(N-[1-methyl-2-(2-thienyl)ethyl-
| ||
4-piperidinyl]-N-phenylpropanamide); | ||
(7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); | ||
(7.1) PEPAP
| ||
(1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); | ||
(8) Benzethidine; | ||
(9) Betacetylmethadol; | ||
(9.1) Beta-hydroxyfentanyl
| ||
(N-[1-(2-hydroxy-2-phenethyl)-
| ||
4-piperidinyl]-N-phenylpropanamide); | ||
(10) Betameprodine; | ||
(11) Betamethadol; | ||
(12) Betaprodine; | ||
(13) Clonitazene; | ||
(14) Dextromoramide; | ||
(15) Diampromide; | ||
(16) Diethylthiambutene; |
(17) Difenoxin; | ||
(18) Dimenoxadol; | ||
(19) Dimepheptanol; | ||
(20) Dimethylthiambutene; | ||
(21) Dioxaphetylbutyrate; | ||
(22) Dipipanone; | ||
(23) Ethylmethylthiambutene; | ||
(24) Etonitazene; | ||
(25) Etoxeridine; | ||
(26) Furethidine; | ||
(27) Hydroxpethidine; | ||
(28) Ketobemidone; | ||
(29) Levomoramide; | ||
(30) Levophenacylmorphan; | ||
(31) 3-Methylfentanyl
| ||
(N-[3-methyl-1-(2-phenylethyl)-
| ||
4-piperidyl]-N-phenylpropanamide); | ||
(31.1) 3-Methylthiofentanyl
| ||
(N-[(3-methyl-1-(2-thienyl)ethyl-
| ||
4-piperidinyl]-N-phenylpropanamide); | ||
(32) Morpheridine; | ||
(33) Noracymethadol; | ||
(34) Norlevorphanol; | ||
(35) Normethadone; | ||
(36) Norpipanone; | ||
(36.1) Para-fluorofentanyl
|
(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
| ||
4-piperidinyl]propanamide); | ||
(37) Phenadoxone; | ||
(38) Phenampromide; | ||
(39) Phenomorphan; | ||
(40) Phenoperidine; | ||
(41) Piritramide; | ||
(42) Proheptazine; | ||
(43) Properidine; | ||
(44) Propiram; | ||
(45) Racemoramide; | ||
(45.1) Thiofentanyl
| ||
(N-phenyl-N-[1-(2-thienyl)ethyl-
| ||
4-piperidinyl]-propanamide); | ||
(46) Tilidine; | ||
(47) Trimeperidine; | ||
(48) Beta-hydroxy-3-methylfentanyl (other name:
| ||
N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
| ||
N-phenylpropanamide). | ||
(c) Unless specifically excepted or unless listed in | ||
another
schedule, any of the following opium derivatives, its | ||
salts, isomers
and salts of isomers, whenever the existence of | ||
such salts, isomers and
salts of isomers is possible within the | ||
specific chemical designation: | ||
(1) Acetorphine; | ||
(2) Acetyldihydrocodeine; |
(3) Benzylmorphine; | ||
(4) Codeine methylbromide; | ||
(5) Codeine-N-Oxide; | ||
(6) Cyprenorphine; | ||
(7) Desomorphine; | ||
(8) Diacetyldihydromorphine (Dihydroheroin); | ||
(9) Dihydromorphine; | ||
(10) Drotebanol; | ||
(11) Etorphine (except hydrochloride salt); | ||
(12) Heroin; | ||
(13) Hydromorphinol; | ||
(14) Methyldesorphine; | ||
(15) Methyldihydromorphine; | ||
(16) Morphine methylbromide; | ||
(17) Morphine methylsulfonate; | ||
(18) Morphine-N-Oxide; | ||
(19) Myrophine; | ||
(20) Nicocodeine; | ||
(21) Nicomorphine; | ||
(22) Normorphine; | ||
(23) Pholcodine; | ||
(24) Thebacon. | ||
(d) Unless specifically excepted or unless listed in | ||
another
schedule, any material, compound, mixture, or | ||
preparation which contains
any quantity of the following | ||
hallucinogenic substances, or which
contains any of its salts, |
isomers and salts of isomers, whenever the
existence of such | ||
salts, isomers, and salts of isomers is possible
within the | ||
specific chemical designation (for the purposes of this
| ||
paragraph only, the term "isomer" includes the optical, | ||
position and
geometric isomers): | ||
(1) 3,4-methylenedioxyamphetamine
| ||
(alpha-methyl,3,4-methylenedioxyphenethylamine,
| ||
methylenedioxyamphetamine, MDA); | ||
(1.1) Alpha-ethyltryptamine
| ||
(some trade or other names: etryptamine;
| ||
MONASE; alpha-ethyl-1H-indole-3-ethanamine;
| ||
3-(2-aminobutyl)indole; a-ET; and AET); | ||
(2) 3,4-methylenedioxymethamphetamine (MDMA); | ||
(2.1) 3,4-methylenedioxy-N-ethylamphetamine
| ||
(also known as: N-ethyl-alpha-methyl-
| ||
3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
| ||
and MDEA); | ||
(2.2) N-Benzylpiperazine (BZP); | ||
(3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); | ||
(4) 3,4,5-trimethoxyamphetamine (TMA); | ||
(5) (Blank); | ||
(6) Diethyltryptamine (DET); | ||
(7) Dimethyltryptamine (DMT); | ||
(7.1) 5-Methoxy-diallyltryptamine; | ||
(8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); | ||
(9) Ibogaine (some trade and other names:
|
7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
| ||
6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
| ||
indole; Tabernanthe iboga); | ||
(10) Lysergic acid diethylamide; | ||
(10.1) Salvinorin A; | ||
(10.5) Salvia divinorum (meaning all parts of the plant | ||
presently classified
botanically as Salvia divinorum, | ||
whether growing or not, the
seeds thereof, any extract from | ||
any part of that plant, and every compound,
manufacture, | ||
salts, isomers, and salts of
isomers whenever the existence | ||
of such salts, isomers, and salts of
isomers is possible | ||
within the specific chemical designation, derivative, | ||
mixture, or preparation of that plant, its
seeds or | ||
extracts);
| ||
(11) 3,4,5-trimethoxyphenethylamine (Mescaline); | ||
(12) Peyote (meaning all parts of the plant presently | ||
classified
botanically as Lophophora williamsii
Lemaire, | ||
whether growing or not, the
seeds thereof, any extract from | ||
any part of that plant, and every compound,
manufacture, | ||
salts, derivative, mixture, or preparation of that plant, | ||
its
seeds or extracts); | ||
(13) N-ethyl-3-piperidyl benzilate (JB 318); | ||
(14) N-methyl-3-piperidyl benzilate; | ||
(14.1) N-hydroxy-3,4-methylenedioxyamphetamine
| ||
(also known as N-hydroxy-alpha-methyl-
| ||
3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); |
(15) Parahexyl; some trade or other names:
| ||
3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
| ||
dibenzo (b,d) pyran; Synhexyl; | ||
(16) Psilocybin; | ||
(17) Psilocyn; | ||
(18) Alpha-methyltryptamine (AMT); | ||
(19) 2,5-dimethoxyamphetamine
| ||
(2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | ||
(20) 4-bromo-2,5-dimethoxyamphetamine
| ||
(4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
| ||
4-bromo-2,5-DMA); | ||
(20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
| ||
Some trade or other names: 2-(4-bromo-
| ||
2,5-dimethoxyphenyl)-1-aminoethane;
| ||
alpha-desmethyl DOB, 2CB, Nexus; | ||
(21) 4-methoxyamphetamine
| ||
(4-methoxy-alpha-methylphenethylamine;
| ||
paramethoxyamphetamine; PMA); | ||
(22) (Blank); | ||
(23) Ethylamine analog of phencyclidine.
| ||
Some trade or other names:
| ||
N-ethyl-1-phenylcyclohexylamine,
| ||
(1-phenylcyclohexyl) ethylamine,
| ||
N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; | ||
(24) Pyrrolidine analog of phencyclidine. Some trade | ||
or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, |
PHP; | ||
(25) 5-methoxy-3,4-methylenedioxy-amphetamine; | ||
(26) 2,5-dimethoxy-4-ethylamphetamine
| ||
(another name: DOET); | ||
(27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
| ||
(another name: TCPy); | ||
(28) (Blank); | ||
(29) Thiophene analog of phencyclidine (some trade
| ||
or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
| ||
2-thienyl analog of phencyclidine; TPCP; TCP); | ||
(30) Bufotenine (some trade or other names:
| ||
3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
| ||
3-(2-dimethylaminoethyl)-5-indolol;
| ||
5-hydroxy-N,N-dimethyltryptamine;
| ||
N,N-dimethylserotonin; mappine); | ||
(31) 1-Pentyl-3-(1-naphthoyl)indole | ||
Some trade or other names: JWH-018; | ||
(32) 1-Butyl-3-(1-naphthoyl)indole | ||
Some trade or other names: JWH-073; | ||
(33) 1-[(5-fluoropentyl)-1H-indol-3-yl]- | ||
(2-iodophenyl)methanone | ||
Some trade or other names: AM-694; | ||
(34) 2-[ ( 1R,3S)-3-hydroxycyclohexyl]-5- | ||
(2-methyloctan-2-yl)phenol | ||
Some trade or other names: CP 47,497 47, 497 | ||
and its C6, C8 and C9 homologs; |
(34.5) (33) 2-[(1R,3S)-3-hydroxycyclohexyl]-5- | ||
(2-methyloctan-2-yl)phenol), where side chain n=5; | ||
and homologues where side chain n=4, 6, or 7; Some | ||
trade or other names: CP 47,497; | ||
(35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- | ||
(2-methyloctan-2-yl)-6a,7, | ||
10,10a-tetrahydrobenzo[c]chromen-1-ol | ||
Some trade or other names: HU-210; | ||
(35.5) (34) (6aS,10aS)-9-(hydroxymethyl)-6,6- | ||
dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- | ||
tetrahydrobenzo[c]chromen-1-ol, its isomers, | ||
salts, and salts of isomers; Some trade or other | ||
names: HU-210, Dexanabinol; | ||
(36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- | ||
6,6-dimethyl-3-(2-methyloctan-2-yl)- | ||
6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | ||
Some trade or other names: HU-211; | ||
(37) (2-methyl-1-propyl-1H-indol- | ||
3-yl)-1-naphthalenyl-methanone | ||
Some trade or other names: JWH-015; | ||
(38) 4-methoxynaphthalen-1-yl- | ||
(1-pentylindol-3-yl)methanone | ||
Some trade or other names: JWH-081; | ||
(39) ( 1-Pentyl-3-(4-methyl-1-naphthoyl)indole | ||
Some trade or other names: JWH-122; | ||
(40) 2-(2-methylphenyl)-1-(1-pentyl- |
1H-indol-3-yl)-ethanone | ||
Some trade or other names: JWH-251; | ||
(41) 1-(2-cyclohexylethyl)-3- | ||
(2-methoxyphenylacetyl)indole | ||
Some trade or other names: RCS-8, BTW-8 and SR-18 ; . | ||
(42) (33) Any compound structurally derived from | ||
3-(1-naphthoyl)indole or 1H-indol-3-yl- | ||
(1-naphthyl)methane by substitution at the | ||
nitrogen atom of the indole ring by alkyl, haloalkyl, | ||
alkenyl, cycloalkylmethyl, cycloalkylethyl or | ||
2-(4-morpholinyl)ethyl whether or not further | ||
substituted in the indole ring to any extent, whether | ||
or not substituted in the naphthyl ring to any extent; | ||
(43) (34) Any compound structurally derived from | ||
3-(1-naphthoyl)pyrrole by substitution at the nitrogen | ||
atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, | ||
cycloalkylmethyl, cycloalkylethyl or | ||
2-(4-morpholinyl)ethyl, whether or not further | ||
substituted in the pyrrole ring to any extent, whether | ||
or not substituted in the naphthyl ring to any extent; | ||
(44) (35) Any compound structurally derived from | ||
1-(1-naphthylmethyl)indene by substitution | ||
at the 3-position of the indene ring by alkyl, haloalkyl, | ||
alkenyl, cycloalkylmethyl, cycloalkylethyl or | ||
2-(4-morpholinyl)ethyl whether or not further | ||
substituted in the indene ring to any extent, whether |
or not substituted in the naphthyl ring to any extent; | ||
(45) (36) Any compound structurally derived from | ||
3-phenylacetylindole by substitution at the | ||
nitrogen atom of the indole ring with alkyl, haloalkyl, | ||
alkenyl, cycloalkylmethyl, cycloalkylethyl or | ||
2-(4-morpholinyl)ethyl, whether or not further | ||
substituted in the indole ring to any extent, whether | ||
or not substituted in the phenyl ring to any extent; | ||
(46) (37) Any compound structurally derived from | ||
2-(3-hydroxycyclohexyl)phenol by substitution | ||
at the 5-position of the phenolic ring by alkyl, | ||
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl | ||
or 2-(4-morpholinyl)ethyl, whether or not substituted | ||
in the cyclohexyl ring to any extent ; . | ||
(47) (33) 3,4-Methylenedioxymethcathinone | ||
Some trade or other names: Methylone; | ||
(48) (34) 3,4-Methyenedioxypyrovalerone | ||
Some trade or other names: MDPV; | ||
(49) (35) 4-Methylmethcathinone | ||
Some trade or other names: Mephedrone; | ||
(50) (36) 4-methoxymethcathinone; | ||
(51) (37) 4-Fluoromethcathinone; | ||
(52) (38) 3-Fluoromethcathinone ; . | ||
(53) (35) 2,5-Dimethoxy-4-(n)-propylthio- | ||
phenethylamine; | ||
(54) (36) 5-Methoxy-N,N-diisopropyltryptamine ; . |
(55) Pentedrone. | ||
(e) Unless specifically excepted or unless listed in | ||
another
schedule, any material, compound, mixture, or | ||
preparation which contains
any quantity of the following | ||
substances having a depressant effect on
the central nervous | ||
system, including its salts, isomers, and salts of
isomers | ||
whenever the existence of such salts, isomers, and salts of
| ||
isomers is possible within the specific chemical designation: | ||
(1) mecloqualone; | ||
(2) methaqualone; and | ||
(3) gamma hydroxybutyric acid. | ||
(f) Unless specifically excepted or unless listed in | ||
another schedule,
any material, compound, mixture, or | ||
preparation which contains any quantity
of the following | ||
substances having a stimulant effect on the central nervous
| ||
system, including its salts, isomers, and salts of isomers: | ||
(1) Fenethylline; | ||
(2) N-ethylamphetamine; | ||
(3) Aminorex (some other names:
| ||
2-amino-5-phenyl-2-oxazoline; aminoxaphen;
| ||
4-5-dihydro-5-phenyl-2-oxazolamine) and its
| ||
salts, optical isomers, and salts of optical isomers; | ||
(4) Methcathinone (some other names:
| ||
2-methylamino-1-phenylpropan-1-one;
| ||
Ephedrone; 2-(methylamino)-propiophenone;
| ||
alpha-(methylamino)propiophenone; N-methylcathinone;
|
methycathinone; Monomethylpropion; UR 1431) and its
| ||
salts, optical isomers, and salts of optical isomers; | ||
(5) Cathinone (some trade or other names:
| ||
2-aminopropiophenone; alpha-aminopropiophenone;
| ||
2-amino-1-phenyl-propanone; norephedrone); | ||
(6) N,N-dimethylamphetamine (also known as:
| ||
N,N-alpha-trimethyl-benzeneethanamine;
| ||
N,N-alpha-trimethylphenethylamine); | ||
(7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
| ||
4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); | ||
(8) 3,4-Methylenedioxypyrovalerone (MDPV). | ||
(g) Temporary listing of substances subject to emergency | ||
scheduling.
Any material, compound, mixture, or preparation | ||
that contains any quantity
of the following substances: | ||
(1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
| ||
(benzylfentanyl), its optical isomers, isomers, salts,
| ||
and salts of isomers; | ||
(2) N-[1(2-thienyl)
| ||
methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
| ||
its optical isomers, salts, and salts of isomers. | ||
(Source: P.A. 96-347, eff. 1-1-10; 96-1285, eff. 1-1-11; | ||
97-192, eff. 7-22-11; 97-193, eff. 1-1-12; 97-194, eff. | ||
7-22-11; 97-334, eff. 1-1-12; revised 9-14-11.)
| ||
Section 15. The Drug Paraphernalia Control Act is amended | ||
by changing Section 2 as follows:
|
(720 ILCS 600/2) (from Ch. 56 1/2, par. 2102)
| ||
Sec. 2. As used in this Act, unless the context otherwise | ||
requires:
| ||
(a) The term "cannabis" shall have the meaning ascribed to | ||
it in Section
3 of the Cannabis Control Act, as if that | ||
definition were incorporated
herein.
| ||
(b) The term "controlled substance" shall have the meaning | ||
ascribed to
it in Section 102 of the Illinois Controlled | ||
Substances Act, as if that
definition were incorporated herein.
| ||
(c) "Deliver" or "delivery" means the actual, constructive | ||
or attempted
transfer of possession, with or without | ||
consideration, whether or not there
is an agency relationship.
| ||
(d) "Drug paraphernalia" means all equipment, products and | ||
materials of
any kind, other than methamphetamine | ||
manufacturing materials as defined in Section 10 of the | ||
Methamphetamine Control and Community Protection Act, which | ||
are intended to be used unlawfully in planting, propagating,
| ||
cultivating, growing, harvesting, manufacturing, compounding,
| ||
converting, producing, processing, preparing, testing, | ||
analyzing, packaging,
repackaging, storing, containing, | ||
concealing, injecting, ingesting, inhaling
or otherwise | ||
introducing into the human body cannabis or a controlled | ||
substance
in violation of the Cannabis Control Act, the | ||
Illinois Controlled
Substances
Act, or the Methamphetamine | ||
Control and Community Protection Act or a synthetic drug |
product or misbranded drug in violation of the Illinois Food, | ||
Drug and Cosmetic Act . It
includes, but is not limited to:
| ||
(1) kits intended to be used unlawfully in | ||
manufacturing, compounding,
converting,
producing, | ||
processing or preparing cannabis or a controlled | ||
substance;
| ||
(2) isomerization devices intended to be used | ||
unlawfully in increasing
the potency of any species of | ||
plant which is cannabis or a controlled
substance;
| ||
(3) testing equipment intended to be used unlawfully in | ||
a private home for
identifying
or in analyzing the | ||
strength, effectiveness or purity of cannabis or | ||
controlled
substances;
| ||
(4) diluents and adulterants intended to be used | ||
unlawfully for cutting
cannabis
or a controlled substance | ||
by private persons;
| ||
(5) objects intended to be used unlawfully in | ||
ingesting, inhaling,
or otherwise introducing cannabis, | ||
cocaine, hashish, or hashish oil , or a synthetic drug | ||
product or misbranded drug in violation of the Illinois | ||
Food, Drug and Cosmetic Act into
the human body including, | ||
where applicable, the following items:
| ||
(A) water pipes;
| ||
(B) carburetion tubes and devices;
| ||
(C) smoking and carburetion masks;
| ||
(D) miniature cocaine spoons and cocaine vials;
|
(E) carburetor pipes;
| ||
(F) electric pipes;
| ||
(G) air-driven pipes;
| ||
(H) chillums;
| ||
(I) bongs;
| ||
(J) ice pipes or chillers;
| ||
(6) any item whose purpose, as announced or described | ||
by the seller, is
for use in violation of this Act.
| ||
(Source: P.A. 93-526, eff. 8-12-03; 94-556, eff. 9-11-05 .)
| ||
Section 99. Effective date. This Act takes effect upon | ||
becoming law. |